D.E. Shaw & Co
CRBP icon

D.E. Shaw & Co’s Corbus Pharmaceuticals CRBP Stock Holding History

D.E. Shaw & Co’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249K Sell
26,474
-2,320
-8% -$19.5K ﹤0.01% 4131
2025
Q4 		$234K Buy
28,794
+18,167
+171% +$224K ﹤0.01% 4268
2025
Q3 		$134K Buy
+10,627
New +$101K ﹤0.01% 4331
2022
Q2 		– Sell
-32,764
Closed -$522K – 5391
2022
Q1 		$522K Buy
32,764
+5,447
+20% +$72.2K ﹤0.01% 4346
2021
Q4 		$505K Buy
27,317
+4,693
+21% +$127K ﹤0.01% 4398
2021
Q3 		$692K Sell
22,624
-1,224
-5% -$48.3K ﹤0.01% 3875
2021
Q2 		$1.31M Buy
23,848
+5,805
+32% +$322K ﹤0.01% 3326
2021
Q1 		$1.07M Sell
18,043
-51,095
-74% -$3.36M ﹤0.01% 3061
2020
Q4 		$2.59M Sell
69,138
-8,045
-10% -$301K ﹤0.01% 2382
2020
Q3 		$4.17M Buy
77,183
+7,905
+11% +$1.43M ﹤0.01% 1828
2020
Q2 		$17.4M Buy
69,278
+27,569
+66% +$5.57M 0.02% 858
2020
Q1 		$6.56M Buy
41,709
+19,204
+85% +$3.25M 0.01% 1253
2019
Q4 		$3.69M Sell
22,505
-2,132
-9% -$315K ﹤0.01% 1985
2019
Q3 		$3.6M Sell
24,637
-7,067
-22% -$1.23M ﹤0.01% 1890
2019
Q2 		$6.59M Sell
31,704
-7,448
-19% -$1.59M 0.01% 1401
2019
Q1 		$8.16M Buy
39,152
+21,315
+119% +$4.7M 0.01% 1241
2018
Q4 		$3.13M Buy
+17,837
New +$3.56M ﹤0.01% 1821
2018
Q1 		– Sell
-396
Closed -$84K – 3532
2017
Q4 		$84K Sell
396
-25
-6% -$5.35K ﹤0.01% 3505
2017
Q3 		$90K Buy
+421
New +$82.4K ﹤0.01% 3375

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's CRBP Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Corbus Pharmaceuticals (CRBP) stake by 8.1% in Q1 2026, selling an estimated $19.5K and leaving 26,474 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #4131.

D.E. Shaw & Co first reported a position in CRBP in Q3 2017 and has held it in 19 quarters since. The position peaked at $17.4M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • D.E. Shaw & Co held 26,474 shares of Corbus Pharmaceuticals worth $249K as of Q1 2026.
  • D.E. Shaw & Co sold 2,320 Corbus Pharmaceuticals shares in Q1 2026, an estimated $19.5K.
  • Corbus Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4131 holding.
  • D.E. Shaw & Co first reported a position in Corbus Pharmaceuticals in Q3 2017 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Corbus Pharmaceuticals position peaked at $17.4M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.